| Company Name: |
Shanghai Synchem Pharma Co., ltd
|
| Tel: |
21-619849051-1 18521059765 |
| Email: |
synchempharma@aliyun.com |
| Products Intro: |
Product Name:Necitumumab
Purity:95%+
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
17754423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Necitumumab
CAS:906805-06-9
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Email: |
sales@dcchemicals.com |
| Products Intro: |
Product Name:Necitumumab (anti-EGFR)
CAS:906805-06-9
Purity:98% HPLC Package:100mg，250mg，1g
|
|
| | Necitumumab Basic information |
| Product Name: | Necitumumab | | Synonyms: | IMC-11F8/LY301221;Necitumumab;Research Grade Necitumumab(DHB86901);Necitumumab (anti-EGFR) | | CAS: | 906805-06-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Necitumumab Structure]() |
| | Necitumumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Necitumumab Usage And Synthesis |
| Clinical Use | IgG1 monoclonal antibody:
Treatment of locally advanced or metastatic
epidermal growth factor receptor (EGFR) expressing
squamous non-small cell lung cancer | | Drug interactions | Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use. | | Metabolism | The elimination routes of necitumumab are only partially
documented, and involve degradation to peptides after
being internalised into its target cells, proteolysis within
the liver or the reticuloendothelial system, as well as
nonspecific endocytosis. |
| | Necitumumab Preparation Products And Raw materials |
|